|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����Ҿ� |
|
�����ҩ |
| ��������������� | |
|
����B |
|
������ |
| PubMed | |
|
Article by |
|
Article by |
�����Ҿ�����һ�������û��ƵĿ����ҩ
����B, ������
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
�����Ҿ���һ�������û��ƵĿ����ҩ,ͨ���Ǿ����Ե��������ϸ�����еĦ�-(1,3)-D-�Ͼ��Ǻϳ�ø,�谭�Ͼ��ǵĺϳ�,�Ӷ�����ɱ�����ԡ���Ҫ�����˿����Ҿ������û��ơ������ס�ҩ������ѧ��ҩ�������á���ҩ��ʽ�ͼ������ٴ���Ч�Լ�������Ӧ��
[2] Stone EA,Fung HB,Kirschenbaum HL.Caspofungin:an echinocandin antifungal agent.Clin Ther,2002,24(3):351-377.
[3] Onishi J,Meinz M,Thompson J,et al.Discovery of novel antifungal(1,3)-beta-D-glucan synthase inhibitors.Antimicrob Agents Chemother,2000,44(2):368-377.
[4] Vicente MF,Basilio A,Cabello A,et al.Microbial natural products as a source of antifungals.Clin Microbiol Infect,2003,9(1):15-32.
[5] Del Poeta M,Cruz MC,Cardenas ME,et al.Synergistic antifungal activities of bafilomycin A(1),fluconazole,and the pneumocandin MK-0991/caspofungin acetate(L-743,873)with calcineurin in-hibitors FKS06 and L-685,818 against Cryptococcus neoformans.Antimicrob Agents Chemother,2000,44(3):739-746.
[6] Bartizal K,Gill C J,Abruzzo GK,et al.In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991(L-743,872).Antimicrob Agents Chemother,1997,41(11):2326-2332.
[7] Graybill JR,Najvar LK,Montalbo EM,et al.Treatment of histoplasmosis with MK-991(L-743,872).Antimicrob Agents Chemother,1998,42(1):151-153.
[8] Del Poeta M,Schell WA,Perfect JR.In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.Antimicrob Agents Chemother,1997,41(8):1835-1836.
[9] Vazquez JA,Lynch M,Boikov D,et al.In vitro activity of a new pneumocandin antifungal,L-743,872,against azole-susceptible and-resistant Candida species.Antimicrob Agents Chemother,1997,41(7):1612-1614.
[10] PoMes MA,Liberator P,Anderson J,et al.Efficacy of MK-991(L-743,872),a semisynthetic pneumocandin,in murine models of Pneumocystis carinii.Antimicrob Agents Chemother,1998,42(8):1985-1989.
[11] Pacetti SA,Gelone SP.Caspofungin acetate for treatment of invasive fungal infections.Ann Pharmacother,2003,37(1):90-98.
[12] Espinel-Ingroff A.Evaluation of broth microdilution testing parametersand agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp.to caspofungin acetate(MK-0991).J Clin Microbiol,2003,41(1):403-409.
[13] Arikan S,Lozano-Chiu M,Paetznick V,et al.In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.Antimicrob Agents Chemother,2001,45(1):327-330.
[14] Hajdu R,Thompson R,Sundelof JG,et al.Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991(L-743,872).Antimicrob Agents Chemother,1997,41(11):2339-2344.
[15] Hoang A.Caspofungin acetate:an antifungal agent.Am J Health Syst Pharm,2001,58(13):1206-1214.
[16] Balani SK,Xu X,Arison BH,et al.Metabolites of easpofungin acetate,a potent antifungal agent,in human plasma and urine.Drug Metab Dispos,2000,28(11):1274-1278.
[17] Abruzzo GK,Flattery AM,Gill CJ,et al.Evaluation of the echinocandin antifungal MK-0991(L-743,872):efficacies in mouse models of disseminated aspergillosis,eandidiasis,and cryptoeoccosis.Antimicrob Agents Chemother,1997,41(11):2333-2338.
[18] Perea S,Patterson TF.Invasive Aspergillus infections in hematologic malignancy patients.Semin Respir Infect,2002,17(2):99-105.
[19] Arathoon EG,Gotuzzo E,Noriega LM,et al.Randomized,doubleblind,multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.Antimicrob Agents Chemother,2002,46(2):451-457.